Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
643
mi
from
Indianapolis, IN
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
190
mi
from
Kansas City, KA
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
190
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1444
mi
from
Boston, MA
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
799
mi
from
Bingham, MI
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
799
mi
from
Bingham, MI
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
830
mi
from
West Bloomfield, MI
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
830
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
418
mi
from
St. Louis, MO
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
418
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1276
mi
from
Toms River, NJ
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1276
mi
from
Toms River, NJ
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1324
mi
from
Commack, NY
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1324
mi
from
Commack, NY
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1288
mi
from
New York, NY
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1288
mi
from
New York, NY
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
858
mi
from
Asheville, NC
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
858
mi
from
Asheville, NC
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
958
mi
from
Charlotte, NC
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
958
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1064
mi
from
Raleigh, NC
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1064
mi
from
Raleigh, NC
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
572
mi
from
Houston, TX
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
572
mi
from
Houston, TX
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
1114
mi
from
Henrico, VA
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
1114
mi
from
Henrico, VA
Click here to add this to my saved trials
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated:  9/21/2012
Clinical Research Facility
635
mi
from
Milwaukee, WI
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)
Status: Enrolling
Updated: 9/21/2012
Clinical Research Facility
635
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative Site
851
mi
from
Phoenix, AZ
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative Site
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative site
1177
mi
from
Los Angeles, CA
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative site
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative site
403
mi
from
Aurora, CO
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative site
403
mi
from
Aurora, CO
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative Site
1320
mi
from
Miami, FL
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative Site
1320
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative site
816
mi
from
Gainesville, GA
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative site
816
mi
from
Gainesville, GA
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative Site
609
mi
from
Chicago, IL
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative Site
609
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative Site
190
mi
from
Overland Park, KA
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative Site
190
mi
from
Overland Park, KA
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative Site
158
mi
from
Oklahoma City, OK
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative Site
158
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated:  10/16/2012
Novartis Investigative site
573
mi
from
Madison, WI
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Status: Enrolling
Updated: 10/16/2012
Novartis Investigative site
573
mi
from
Madison, WI
Click here to add this to my saved trials
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4
Status: Enrolling
Updated:  10/18/2012
Clinical Research Facility
1287
mi
from
Atlantis, FL
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4
Status: Enrolling
Updated: 10/18/2012
Clinical Research Facility
1287
mi
from
Atlantis, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
859
mi
from
Sun City, AZ
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
859
mi
from
Sun City, AZ
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
835
mi
from
Tucson, AZ
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
835
mi
from
Tucson, AZ
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
835
mi
from
Tucson, AZ
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
835
mi
from
Tucson, AZ
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1160
mi
from
Fountain Valley, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1160
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1207
mi
from
Fresno, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1207
mi
from
Fresno, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1153
mi
from
Fullerton, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1153
mi
from
Fullerton, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1152
mi
from
Irvine, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1152
mi
from
Irvine, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1171
mi
from
Long Beach, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1171
mi
from
Long Beach, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1215
mi
from
Oxnard, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1215
mi
from
Oxnard, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1348
mi
from
Santa Rosa, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1348
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1322
mi
from
Sunnyvale, CA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1322
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
430
mi
from
Boulder, CO
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
430
mi
from
Boulder, CO
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
408
mi
from
Englewood, CO
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
408
mi
from
Englewood, CO
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1287
mi
from
Atlantis, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1287
mi
from
Atlantis, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1132
mi
from
Bradenton, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1132
mi
from
Bradenton, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1049
mi
from
Gainesville, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1309
mi
from
Hollywood, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1309
mi
from
Hollywood, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1231
mi
from
Naples, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1231
mi
from
Naples, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1298
mi
from
Sunrise, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1298
mi
from
Sunrise, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1297
mi
from
Tamarac, FL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1297
mi
from
Tamarac, FL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
803
mi
from
Atlanta, GA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
798
mi
from
Atlanta, GA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
798
mi
from
Atlanta, GA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
596
mi
from
Elk Grove Village, IL
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
596
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1444
mi
from
Boston, MA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
1444
mi
from
Boston, MA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials